OC
VCNX

Oppenheimer & Co’s Vaccinex, Inc. Common Stock VCNX Stock Holding History

Oppenheimer & Co’s Portfolio VCNX Stock Details VCNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-68
Closed -$19K – 1557
2022
Q1 		$19K Hold
68
– – ﹤0.01% 1457
2021
Q4 		$15K Sell
68
-83
-55% -$29.9K ﹤0.01% 1482
2021
Q3 		$69K Sell
151
-49
-25% -$24.4K ﹤0.01% 1464
2021
Q2 		$117K Sell
200
-5
-2% -$2.64K ﹤0.01% 1465
2021
Q1 		$128K Sell
205
-65
-24% -$41.8K ﹤0.01% 1392
2020
Q4 		$117K Buy
270
+158
+141% +$66.1K ﹤0.01% 1302
2020
Q3 		$42K Sell
112
-56
-33% -$61.1K ﹤0.01% 1264
2020
Q2 		$128K Buy
168
+36
+27% +$28.1K ﹤0.01% 1184
2020
Q1 		$111K Sell
132
-7
-5% -$7.93K ﹤0.01% 1106
2019
Q4 		$142K Buy
139
+1
+0.7% +$1.13K ﹤0.01% 1221
2019
Q3 		$207K Buy
138
+63
+84% +$70.9K 0.01% 1124
2019
Q2 		$87K Buy
+75
New +$100K ﹤0.01% 1268

Other funds holding VCNX

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Oppenheimer & Co's VCNX Position: Q2 2022 in Review

Oppenheimer & Co sold out of Vaccinex, Inc. Common Stock (VCNX) in Q2 2022, closing a stake of 68 shares — an estimated $19K sold.

Oppenheimer & Co first reported a position in VCNX in Q2 2019 and held it in 12 quarters. The position peaked at $207K in Q3 2019. 27 funds tracked by Wall St. Rank hold VCNX as of Q2 2022.

  • Oppenheimer & Co reported no remaining Vaccinex, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 68 Vaccinex, Inc. Common Stock shares in Q2 2022, an estimated $19K.
  • Oppenheimer & Co first reported a position in Vaccinex, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Oppenheimer & Co's Vaccinex, Inc. Common Stock position peaked at $207K in Q3 2019.
  • 27 funds tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q2 2022.

Based on Oppenheimer & Co's 13F filing for Q2 2022, filed 8 Aug 2022.